Search

Displaying results 1811 - 1820 of 4589 in total
  1. Drug

    Izencitinib

    go.drugbank.com/drugs/DB16660
    Investigational

    Izencitinib is under investigation in clinical trial NCT03920254 (TD-1473 Long-term Safety (LTS) Ulcerative Colitis (UC) Study).

  2. Drug

    MK-0777

    go.drugbank.com/drugs/DB12238
    Investigational

    MK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.

  3. Drug

    Ciforadenant

    go.drugbank.com/drugs/DB16125
    Investigational

    Ciforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)).

  4. Drug

    Chlorpropamide

    go.drugbank.com/drugs/DB00672
    ApprovedWithdrawn

    It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. … Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites.

  5. Drug

    Calcium gluconate

    go.drugbank.com/drugs/DB11126
    ApprovedInvestigationalVet approved

    It can also be taken by mouth but is not recommended by injection into a muscle.

  6. Drug

    Polihexanide

    go.drugbank.com/drugs/DB12277
    ApprovedInvestigational

    [A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite. … Structurally, it consists of repeating biguanide units linked by hexamethylene hydrocarbon chains, conferring both hydrophilic and hydrophobic properties that enhance its interaction with microbial membranes

  7. Drug

    Virus Specific T-Cell

    go.drugbank.com/drugs/DB15735
    Investigational

    Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation.

  8. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November

  9. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    [A181409,A181535,A181538,A1793] Study data has confirmed that pitavastatin's potency in lowering LDL-C is comparable to that of other statins but also has increased efficacy in increasing HDL-C (also known … By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease.

  10. Drug

    Tizanidine

    go.drugbank.com/drugs/DB00697
    ApprovedInvestigational

    Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons … It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.